[{"id":"a1bfec25-d893-4cf6-93c8-c3f71ddf2444","acronym":"DURANCE","url":"https://clinicaltrials.gov/study/NCT04106115","created_at":"2021-01-18T20:04:52.084Z","updated_at":"2025-02-25T15:08:49.394Z","phase":"Phase 1/2","brief_title":"DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr","source_id_and_acronym":"NCT04106115 - DURANCE","lead_sponsor":"University College, London","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • S-588210"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-12-04"},{"id":"0793356c-e4c6-44d6-9e43-f34c54e86834","acronym":"","url":"https://clinicaltrials.gov/study/NCT02661659","created_at":"2021-06-30T14:52:53.342Z","updated_at":"2024-07-02T16:37:10.793Z","phase":"Phase 1","brief_title":"A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy","source_id_and_acronym":"NCT02661659","lead_sponsor":"University of Chicago","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S-588210"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/12/2016","start_date":" 06/12/2016","primary_txt":" Primary completion: 10/03/2017","primary_completion_date":" 10/03/2017","study_txt":" Completion: 10/03/2017","study_completion_date":" 10/03/2017","last_update_posted":"2018-05-14"}]